J Vet Sci.  2011 Sep;12(3):215-219. 10.4142/jvs.2011.12.3.215.

Effects of hydrocortisone and aminophylline on the aggregation of equine platelets in vitro

Affiliations
  • 1Department of Experimental Science and Applied Biotechnology, Laboratory of Chronophysiology, University of Messina, Messina 98168, Italy. giuseppe.piccione@unime.it
  • 2Department of Public Health, Faculty of Veterinary Medicine, University of Messina, Messina 98168, Italy.

Abstract

The purpose of this study was to evaluate in vitro the effects of hydrocortisone and aminophylline on adenosine diphosphate (ADP)-induced platelet aggregation in horses. Blood samples from 30 healthy Thoroughbred horses were collected by via jugular venipuncture to assess platelet aggregation. Platelet-rich and platelet-poor plasma were prepared from all samples by centrifugation and divided into three different aliquots. In the first aliquot, platelet aggregation was measured after platelet activation with 1 microM and 0.5 microM ADP (Group A). In the other two aliquots, the effect of a 10 min preincubation with hydrocortisone (Group B) or aminophylline (Group C) on ADP-induced aggregation at final ADP concentrations of 1 microM and 0.5 microM was observed. Platelet aggregation, recorded by an aggregometer, was evaluated by measuring the maximum degree of platelet aggregation and the initial velocities of platelet aggregation were obtained. Our results demonstrated the inhibitory effect of hydrocortisone and the induction effect of aminophylline on equine platelet responses in vitro.

Keyword

adenosine diphosphate; aminophylline; horse; hydrocortisone; platelets

MeSH Terms

Adenosine Diphosphate/pharmacology
Aminophylline/*pharmacology
Animals
Anti-Inflammatory Agents/*pharmacology
Female
Horses/*physiology
Hydrocortisone/*pharmacology
Male
Platelet Aggregation/*drug effects

Figure

  • Fig. 1 Average values of the maximum degree of platelet aggregation expressed as a percentage and the initial velocity of platelet aggregation expressed as the percentage per 1 min for samples from Group A (adenosine diphosphate [ADP]-induced platelet aggregation), Group B (ADP-induced platelet aggregation with hydrocortisone pre-incubation), and Group C (ADP-induced platelet aggregation with aminophylline pre-incubation). Values were measured in the presence of final ADP concentrations of 1 µM and 0.5 µM. *vs. Group A (p < 0.05), •vs. Group B (p < 0.001).


Reference

1. Angelucci L. The glucocorticoid hormone: from pedestal to dust and back. Eur J Pharmacol. 2000. 405:139–147.
Article
2. Birks EK, Durando MM, Martin BBJ. Hinchcliff KW, Kaneps AJ, Geor RJ, editors. Clinical exercise testing: evaluation of the poor performing athlete. Equine Sports Medicine and Surgery. 2004. 1st ed. Edinburgh: Saunders;1–19.
Article
3. Blajchman MA, Senyi AF, Hirsh J, Surya Y, Buchanan M, Mustard JF. Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest. 1979. 63:1026–1035.
Article
4. Brinson K. Effect of aminophylline on blood platelet reactions. Atherosclerosis. 1972. 16:233–239.
Article
5. Bygdeman S, Johnsen O. Methyl xantines in the inhibition of platelet aggregation. Acta Med Scand Suppl. 1971. 525:179–182.
Article
6. Cambridge H, Lees P, Hooke RE, Russell CS. Antithrombotic actions of aspirin in the horse. Equine Vet J. 1991. 23:123–127.
Article
7. Casella S, Giudice E, Alberghina S, Giannetto C, Marafioti S, Piccione G. Hydrocortisone inhibition of adenosine diphosphate (ADP)-induced platelet aggregation in horse. Comp Clin Path. 2011. 20:327–331.
Article
8. Choi JW. Influence of caffeine on the responsiveness of human platelet to agonists. Thromb Res. 2003. 110:209–212.
Article
9. Clemmons RM, Meyers KM. Acquisition and aggregation of canine blood platelets: basic mechanisms of function and differences because of breed origin. Am J Vet Res. 1984. 45:137–144.
10. Errecalde JO, Button C, Baggot JD, Mulders MSG. Pharmacokinetics and bioavailability of theophylline in horses. J Vet Pharmacol Ther. 1984. 7:255–263.
Article
11. Gachet C. Platelet activation by ADP: the role of ADP antagonists. Ann Med. 2000. 32:Suppl 1. 15–20.
12. Gader AMA, Al Ghumlas AK, Hussai MF, Al Haidary AI. Platelet aggregation and platelet function analyzer 100 (PFA-100) closure time in camels-a comparative study with humans. Comp Clin Path. 2006. 15:31–37.
Article
13. Gilbert RM, Bird KE, Kutzler MA. Platelet aggregation responses in clinically healthy adult llamas. Vet Clin Pathol. 2009. 38:42–45.
Article
14. Goetz TE, Munsiff IJ, McKiernan BC. Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. J Vet Pharmacol Ther. 1989. 12:369–377.
Article
15. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007. 109:5087–5095.
Article
16. Jarvis GE, Humphries RG, Robertson MJ, Leff P. ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. Br J Pharmacol. 2000. 129:275–282.
Article
17. Johnstone IB. Comparative effects of phenylbutazone, naproxen and flunixin in meglumine on equine platelet aggregation and platelet factor 3 availability in vitro. Can J Comp Med. 1983. 47:172–179.
18. Kawai H, Kokubun S, Matsumoto T, Kojima J, Onodera K. Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine. Methods Find Exp Clin Pharmacol. 2000. 22:179–184.
19. Lakin KM, Ovnatanova MS, Matyashova MA, Mashkovskii MD. Investigation of the effect of some xanthine derivatives on platelet aggregation and other indices of hemostasis. Bull Exp Biol Med. 1980. 89:159–160.
Article
20. Lewis GP, Piper PJ. Inhibition of release of prostaglandins as an explanation of some of the actions of anti-inflammatory corticosteroids. Nature. 1975. 254:308–311.
Article
21. Lindahl TL, Ramström S. Methods for evaluation of platelet function. Transfus Apher Sci. 2009. 41:121–125.
Article
22. Meyers KM, Lindner C, Katz J, Grant B. Phenylbutazone inhibition of equine platelet function. Am J Vet Res. 1979. 40:265–270.
23. Monreal L, Anglés A, Espada Y, Monasterio J, Monreal M. Hypercoagulation and hypofibrinolysis in horses with colic and DIC. Equine Vet J Suppl. 2000. 32:19–25.
Article
24. Moore JN, Barton MH. An update on endotoxaemia. Part 1: mechanisms and pathways. Equine Vet Educ. 1998. 10:300–306.
Article
25. Nenci GG. Platelet aggregation and platelet-inhibiting drugs. Neurochem Pathol. 1987. 7:23–32.
Article
26. Pelagalli A, Lombardi P, d'Angelo D, Della Morte R, Avallone L, Staiano N. Species variability in platelet aggregation response to different agonists. J Comp Pathol. 2002. 127:126–132.
Article
27. Pelagalli A, Ciaramella P, Lombardi P, Pero ME, Cortese L, Corona M, Oliva G, Avallone L. Evaluation of adenosine 5'-diphosphate (ADP)- and collagen-induced platelet aggregation in canine leishmaniasis. J Comp Pathol. 2004. 130:124–129.
Article
28. Piccione G, Casella S, Giannetto C, Assenza A, Caola G. Effect of different storage conditions on platelet aggregation in horse. J Equine Vet Sci. 2010. 30:371–375.
Article
29. Puustinen T, Uotila P. The effect of hydrocortisone on the metabolism of PGE2 in rat lungs. Prostaglandins Leukot Med. 1982. 9:479–482.
Article
30. Rickards KJ, Andrews MJ, Waterworth TH, Alexander GBC, Cunningham FM. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther. 2003. 26:277–282.
Article
31. Schuerholz T, Keil O, Wagner T, Klinzing S, Sümpelmann R, Oberle V, Marx G. Hydrocortisone does not affect major platelet receptors in inflammation in vitro. Steroids. 2007. 72:609–613.
Article
32. Segura D, Monreal L, Espada Y, Pastor J, Mayós I, Homedes J. Assessment of a platelet function analyser in horses: reference range and influence of a platelet aggregation inhibitor. Vet J. 2005. 170:108–112.
Article
33. Sergeev PV, Dukhanin AS, Gubaeva FR. Early stages in the mechanism of action of glucocorticoids on human platelets. The effect of hydrocortisone on platelet aggregation. Biull Eksp Biol Med. 1997. 123:54–57.
34. Soloviev MV, Okazaki Y, Harasaki H. Whole blood platelet aggregation in humans and animals: a comparative study. J Surg Res. 1999. 82:180–187.
Article
35. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971. 231:235–237.
Article
36. Thomas JS. Comparison of platelet aggregation and adenosine triphosphate secretion in whole blood and platelet-rich plasma from normal dogs. Comp Haematol Int. 1996. 6:70–76.
Article
37. Thrall MA, Baker DC, Campbell TW, DeNicola D, Fettman MJ, Lassen ED, Rebar A, Weiser G. Veterinary Hematology and Clinical Chemistry. 2004. 1st ed. Philadelphia: Lippincott Williams & Wilkins.
38. Weber G, Bianciardi G, Toti P, Massari P, Orlando P. Observations on the effects of some anti-aggregating drugs on platelet specific protein discharge after a very weak stimulus. Pharmacol Res Commun. 1985. 17:129–135.
Article
Full Text Links
  • JVS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr